An 18-Year Overview of Serratia marcescens Ocular Infection.
Journal
Eye & contact lens
ISSN: 1542-233X
Titre abrégé: Eye Contact Lens
Pays: United States
ID NLM: 101160941
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
accepted:
09
04
2021
pubmed:
30
5
2021
medline:
18
8
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
Serratia marcescens is a frequent ocular bacterial pathogen implicated in keratitis, endophthalmitis, and conjunctivitis. We evaluated the risk factors and treatment outcomes of ocular infections due to S. marcescens. In this retrospective observational study, all S. marcescens-positive cases between February 2002 and February 2020 were reviewed for ocular risk factors that included log of minimal angle of resolution visual acuity (VA), medical management, and time to epithelial defect closure. Fifty-one patients were identified (72.5% females, 46.8±23.3 years). Forty-six patients had complete medical records, and 5 had microbiology data available. The most prevalent ocular risk factors were, contact lens (CL) use (68.6%), corneal disease (52.9%), and history of ocular surgery (41.2%). Mean presenting VA was 1.3±1.0. About half of the patients presented with a central ulcer (49%, 25), large infiltrate (20.4±31.8 mm2 mean), and hypopyon (43.1%, 22). All cases were reported to be susceptible to ciprofloxacin. Defect closure occurred in 52.3±117.1 days and final VA was 0.86±0.88. Adjunctive treatments were required in 14 cases (27.5%). One patient underwent surgical intervention. Features associated with poor VA outcomes included, history of glaucoma (P=0.038), older age at presentation (P<0.001), presence of hypopyon (0.045), poor VA at presentation (0.0086), time to epithelial defect closure (0.0196), and large infiltrate size (P=0.0345). S. marcescens keratitis and conjunctivitis is associated with CL use and history of ocular surface disease. Worse outcomes were associated with older age, infiltrate size, presence of hypopyon, worse initial VA, longer time to epithelial defect closure, and history of glaucoma.
Identifiants
pubmed: 34050088
doi: 10.1097/ICL.0000000000000803
pii: 00140068-202108000-00007
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-475Informations de copyright
Copyright © 2021 Contact Lens Association of Ophthalmologists.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Mahlen SD. Serratia infections: From military experiments to current practice. Clin Microbiol Rev 2011;24:755–791.
Cristina ML, Sartini M, Spagnolo AM. Serratia marcescens infections in neonatal intensive care units (NICUs). Int J Environ Res Public Health 2019;16:610.
Iguchi A, Nagaya Y, Pradel E, et al. Genome evolution and plasticity of Serratia marcescens, an important multidrug-resistant nosocomial pathogen. Genome Biol Evol 2014;6:2096–2110.
Rodrigues AP, Holanda AR, Lustosa GP, et al. Virulence factors and resistance mechanisms of Serratia marcescens. A short review. Acta Microbiol Immunol Hung 2006;53:89–93.
Abreo E, Altier N. Pangenome of Serratia marcescens strains from nosocomial and environmental origins reveals different populations and the links between them. Sci Rep 2019;9:46.
Samonis G, Vouloumanou EK, Christofaki M, et al. Serratia infections in a general hospital: Characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2011;30:653–660.
Bigger JF, Meltzer G, Mandell A, Burde RM. Serratia marcescens endophthalmitis. Am J Ophthalmol 1971;72:1102–1105.
Shanks RM, Stella NA, Hunt KM, et al. Identification of SlpB, a cytotoxic protease from Serratia marcescens. Infect Immun 2015;83:2907–2916.
Matsumoto K. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol Chem 2004;385:1007–1016.
Zhou R, Zhang R, Sun Y, et al. Innate immune regulation of Serratia marcescens-induced corneal inflammation and infection. Invest Ophthalmol Vis Sci 2012;53:7382–7388.
Mah-Sadorra JH, Najjar DM, Rapuano CJ, et al. Serratia corneal ulcers: A retrospective clinical study. Cornea 2005;24:793–800.
Varaprasathan G, Miller K, Lietman T, et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor Foundation. Cornea 2004;23:360–364.
Karaca I, Barut Selver O, Palamar M, et al. Contact lens-associated microbial keratitis in a tertiary eye care center in Turkey. Eye Contact Lens 2020;46:110–115.
Pinna A, Usai D, Sechi LA, et al. Detection of virulence factors in Serratia strains isolated from contact lens-associated corneal ulcers. Acta Ophthalmol 2011;89:382–387.
Spernovasilis N, Maraki S, Kokorakis E, et al. Antimicrobial susceptibility of isolated pathogens from patients with contact lens-related bacterial keratitis in crete, Greece: A ten-year analysis. Cont Lens Anterior Eye 2020;101355.
Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497–1502.
Cho CH, Lee SB. Comparison of clinical characteristics and antibiotic susceptibility between Pseudomonas aeruginosa and P. Putida keratitis at a tertiary referral center: A retrospective study. BMC Ophthalmol 2018;18:204.
Durrani AF, Atta S, Bhat AK, et al. Methicillin-resistant Staphylococcus aureus keratitis: Initial treatment, risk factors, clinical features, and treatment outcomes. Am J Ophthalmol 2020;214:119–126.
Durrani AF, Faith SC, Kowalski RP, et al. Moraxella keratitis: Analysis of risk factors, clinical characteristics, management, and treatment outcomes. Am J Ophthalmol 2019;197:17–22.
Templeton WC III, Eiferman RA, Snyder JW, et al. Serratia keratitis transmitted by contaminated eyedroppers. Am J Ophthalmol 1982;93:723–726.
Tsegaw A, Tsegaw A, Abula T, Assefa Y. Bacterial contamination of multi-dose eye drops at Ophthalmology department, University of Gondar, Northwest Ethiopia. Middle East Afr J Ophthalmol 2017;24:81–86.
Khoo P, Cabrera-Aguas MP, Nguyen V, et al. Microbial keratitis in Sydney, Australia: Risk factors, patient outcomes, and seasonal variation. Graefes Arch Clin Exp Ophthalmol 2020;258:1745–1755.
Kowalski RP, Kowalski TA, Shanks RM, et al. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection. Cornea 2013;32:830–834.
Atlee WE, Burns RP, Oden M. Serratia marcescens keratoconjunctivitis. Am J Ophthalmol 1970;70:31–33.